Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lioudmila Kinachtchouk

Internal Medicine Saginaw, MI Medical Doctor

NPI 1124012786 CMS profile 231656

4705 Towne Ctr, Suite 102, Saginaw, MI 48604

Open in the dashboard

General payments

$8,534

530 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lioudmila Kinachtchouk of Saginaw, MI is reported in the CMS Open Payments database as having received $8,534 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,205 62
2024 General $1,179 64
2023 General $1,293 66
2022 General $1,346 82
2021 General $865 59
2020 General $992 68
2019 General $1,653 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lioudmila Kinachtchouk
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lioudmila Kinachtchouk were reported at $1,205. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lioudmila Kinachtchouk Internal Medicine median Middle half National median
2019 $1,653 $159 $48–$570 $163
2020 $992 $119 $33–$402 $114
2021 $865 $135 $37–$521 $132
2022 $1,346 $141 $42–$496 $149
2023 $1,293 $149 $45–$519 $160
2024 $1,179 $154 $47–$537 $164
2025 $1,205 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,245 110 payments
  2. Lilly USA, LLC $782 51 payments
  3. Pfizer Inc. $585 43 payments
  4. AstraZeneca Pharmaceuticals LP $535 35 payments
  5. Amgen Inc. $518 27 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $512 30 payments
  7. Merck Sharp & Dohme Corporation $477 35 payments
  8. Abbott Laboratories $403 16 payments
  9. Novartis Pharmaceuticals Corporation $375 21 payments
  10. Merz North America, Inc. $356 3 payments
  11. Other $2,746 159 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,502 528 payments
  2. Education $32 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $510 33 payments
  2. RYBELSUS $460 25 payments
  3. FARXIGA $422 28 payments
  4. MOUNJARO $376 24 payments
  5. Repatha $342 17 payments
  6. FreeStyle Libre 3 $310 11 payments
  7. JARDIANCE Diabetes $301 21 payments
  8. Otezla $300 15 payments
  9. Kerendia $268 16 payments
  10. JARDIANCE Diabetes $257 16 payments
  11. Other $7,399 468 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

5,323

Median for Internal Medicine: 777

Drug cost

$641,337

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 129 $147,764
Ozempic Semaglutide Brand 68 $99,232
Trulicity Dulaglutide Brand 60 $74,481
Jardiance Empagliflozin Brand 45 $71,128
Mounjaro Tirzepatide Brand 32 $51,972
Farxiga Dapagliflozin Propanediol Brand 43 $39,481
Myrbetriq Mirabegron Brand 19 $19,085
Synjardy Empagliflozin/Metformin Hcl Brand 17 $15,126
Rosuvastatin Calcium Generic 496 $10,250
Synjardy Xr Empagliflozin/Metformin Hcl Brand 11 $8,385

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$57,052

Of which drugs: $11,276

Medicare patients

161

Average age 78

Services billed

901

120 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 35%
Diabetes 33%
Ischemic heart disease 32%
Depression 30%
Atrial fibrillation 29%
Osteoporosis 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 31 31 $8,990
Vaccine for influenza for injection into muscle 90653 Office 26 26 $2,127
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 62 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $63
  • PFIZER INC. $28
$91 129 —
MOUNJARO
  • Lilly USA, LLC $90
$90 32 —
Veozah
  • Astellas Pharma US Inc $88
$88 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $84
$84 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $58
  • Lilly USA, LLC $24
$83 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record